364 related articles for article (PubMed ID: 26374217)
1. Regulatory Frameworks for Gene and Cell Therapies in Japan.
Maeda D; Yamaguchi T; Ishizuka T; Hirata M; Takekita K; Sato D
Adv Exp Med Biol; 2015; 871():147-62. PubMed ID: 26374217
[TBL] [Abstract][Full Text] [Related]
2. Regulatory Oversight of Gene Therapy and Cell Therapy Products in Korea.
Choi M; Han E; Lee S; Kim T; Shin W
Adv Exp Med Biol; 2015; 871():163-79. PubMed ID: 26374218
[TBL] [Abstract][Full Text] [Related]
3. Regulatory Aspects of Cell and Gene Therapy Products: The Japanese Perspective.
Maruyama Y; Noda S; Okudaira S; Sakurai A; Okura N; Honda F
Adv Exp Med Biol; 2023; 1430():155-179. PubMed ID: 37526847
[TBL] [Abstract][Full Text] [Related]
4. Marketing Regulatory Oversight of Advanced Therapy Medicinal Products (ATMPs) in Europe: The EMA/CAT Perspective.
Salmikangas P; Schuessler-Lenz M; Ruiz S; Celis P; Reischl I; Menezes-Ferreira M; Flory E; Renner M; Ferry N
Adv Exp Med Biol; 2015; 871():103-30. PubMed ID: 26374215
[TBL] [Abstract][Full Text] [Related]
5. Requirements for Clinical Trials with Gene Therapy and Transplant Products in Switzerland.
Marti A
Adv Exp Med Biol; 2015; 871():131-45. PubMed ID: 26374216
[TBL] [Abstract][Full Text] [Related]
6. Regulation of Cell and Gene Therapy Medicinal Products in Taiwan.
Lin YC; Wang PY; Tsai SC; Lin CL; Tai HY; Lo CF; Wu SI; Chiang YM; Liu LL
Adv Exp Med Biol; 2015; 871():181-94. PubMed ID: 26374219
[TBL] [Abstract][Full Text] [Related]
7. Regulation of Clinical Trials with Advanced Therapy Medicinal Products in Germany.
Renner M; Anliker B; Sanzenbacher R; Schuele S
Adv Exp Med Biol; 2015; 871():87-101. PubMed ID: 26374214
[TBL] [Abstract][Full Text] [Related]
8. Regulatory Oversight of Cell- and Tissue-Based Therapeutic Products and Gene Therapy Products in Singapore.
Goh CW; Kellathur SN; Ong LL; Wu X
Adv Exp Med Biol; 2015; 871():195-212. PubMed ID: 26374220
[TBL] [Abstract][Full Text] [Related]
9. Overview of the Regulatory Oversight Implemented by the French Regulatory Authorities for the Clinical Investigation of Gene Therapy and Cell Therapy Products.
Lucas-Samuel S; Ferry N; Trouvin JH
Adv Exp Med Biol; 2015; 871():73-85. PubMed ID: 26374213
[TBL] [Abstract][Full Text] [Related]
10. Regulatory Oversight of Cell and Gene Therapy Products in Canada.
Ridgway A; Agbanyo F; Wang J; Rosu-Myles M
Adv Exp Med Biol; 2015; 871():49-71. PubMed ID: 26374212
[TBL] [Abstract][Full Text] [Related]
11. The Regulatory Pathway for Advanced Cell Therapy and Gene Therapy Products in Brazil: A Road to Be Built.
de Freitas DR
Adv Exp Med Biol; 2015; 871():213-9. PubMed ID: 26374221
[TBL] [Abstract][Full Text] [Related]
12. United States Food and Drug Administration Regulation of Gene and Cell Therapies.
Bailey AM; Arcidiacono J; Benton KA; Taraporewala Z; Winitsky S
Adv Exp Med Biol; 2015; 871():1-29. PubMed ID: 26374210
[TBL] [Abstract][Full Text] [Related]
13. Regenerative medicine legislation in Japan for fast provision of cell therapy products.
Fujita Y; Kawamoto A
Clin Pharmacol Ther; 2016 Jan; 99(1):26-9. PubMed ID: 26482927
[TBL] [Abstract][Full Text] [Related]
14. [Translational/regulatory science researches of NIHS for regenerative medicine and cellular therapy products].
Sato Y
Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2014; (132):6-9. PubMed ID: 25707195
[TBL] [Abstract][Full Text] [Related]
15. New Japanese Regulatory Frameworks for Clinical Research and Marketing Authorization of Gene Therapy and Cellular Therapy Products.
Nagai S; Ozawa K
Curr Gene Ther; 2017; 17(1):17-28. PubMed ID: 28382858
[TBL] [Abstract][Full Text] [Related]
16. Regulatory perspectives of Japan.
Kusakabe T
Biologicals; 2015 Sep; 43(5):422-4. PubMed ID: 26028474
[TBL] [Abstract][Full Text] [Related]
17. The National Institutes of Health Oversight of Human Gene Transfer Research: Enhancing Science and Safety.
O'Reilly M; Jambou R; Rosenthal E; Montgomery M; Hassani M; Gargiulo L; Corrigan-Curay J
Adv Exp Med Biol; 2015; 871():31-47. PubMed ID: 26374211
[TBL] [Abstract][Full Text] [Related]
18. Pharmacovigilance of Regenerative Medicine Under the Amended Pharmaceutical Affairs Act in Japan.
Inokuma Y
Drug Saf; 2017 Jun; 40(6):475-482. PubMed ID: 28299610
[TBL] [Abstract][Full Text] [Related]
19. Reflection on the enactment and impact of safety laws for regenerative medicine in Japan.
Takashima K; Morrison M; Minari J
Stem Cell Reports; 2021 Jun; 16(6):1425-1434. PubMed ID: 34019814
[TBL] [Abstract][Full Text] [Related]
20. First Approval of Regenerative Medical Products under the PMD Act in Japan.
Konishi A; Sakushima K; Isobe S; Sato D
Cell Stem Cell; 2016 Apr; 18(4):434-5. PubMed ID: 27058934
[No Abstract] [Full Text] [Related]
[Next] [New Search]
